凯时注射液治疗糖尿病膀胱病临床研究

Study of efficacy of Lipo PGE_1 in treatment of diabetic cystopathy

目的 研究前列腺素E1脂微球载体制剂 (LipoPGE1,凯时 )治疗糖尿病膀胱病的临床疗效及其不良反应。方法 对确诊为糖尿病膀胱病的 32例患者 ,给予LipoPGE110 μg/d ,共 2周。对照组 30例 ,除不加用LipoPGE1外 ,余治疗与治疗组相同。结果 治疗组应用LipoPGE1治疗 2周后 ,患者主观症状和体征有较明显改善 ,总有效率达 90 .6 % ,而对照组有效率仅达 4 3.8% ,两组相比 ,差异有非常显著性 (P <0 .0 1)。两组膀胱尿残余量(BRU)测定 :治疗组较对照治疗前差异有显著性 (P <0 .0 5 ) ,而对照组治疗前后无明显变化。治疗前后测量两组肌电图的结果分析与膀胱残余尿的类似。药物治疗过程中未见明显不良反应。

Objective To study the efficacy and tolerability of Lipo PGE 1 in treatment of diabetic cystopathy.Methods Thirty two patients with diabetic cystopathy(DCP) were treated with Lipo PGE 1(daily,10 ug),another 30 patients were treated without Lipo PGE 1.Results After 2 weeks treatment,the subjective symptoms and signs were improved significantly with a total effective rate of 90.6% in the treatment group versus 43.8% in the control group( P <0.01).The bladder residue urine(BRU) decreased and the motor nerve conduction velocity improved significantly in the treatment group,and no such changes were observed in the control group(both P < 0.05 ),No obvious adverse reactions were found.Conclusion Lipo PGE 1 is an effective and safe agent for treatment of diabetic cystopathy.